Guillain-Barré syndrome (Q24276200)

Europe PubMed Central

title

Guillain-Barré syndrome (English)

0 references

main subject

Guillain–Barré syndrome

0 references

2

David R Cornblath

0 references

author name string

Richard A C Hughes

series ordinal

1

0 references

language of work or name

English

0 references

publication date

5 November 2005

0 references

published in

The Lancet

0 references

volume

366

0 references

issue

9497

0 references

page(s)

1653-66

0 references

cites work

Guillain-Barré syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Guillain-Barré syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Pathology of the motor-sensory axonal Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Epidemiological, clinical, and electrodiagnostic findings in childhood Guillain-Barré syndrome: a reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Autonomic function in demyelinating and axonal subtypes of Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

An Unusual Variant of Acute Idiopathic Polyneuritis (Syndrome of Ophthalmoplegia, Ataxia and Areflexia)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Clinical and epidemiologic features of Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Epidemiological study of Guillain-Barré syndrome in south east England

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Incidence and clinical features of acute inflammatory polyradiculoneuropathy in Lombardy, Italy, 1996.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Guillain-Barré syndrome: a prospective, population-based incidence and outcome survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Epidemiology of the Guillain-Barré syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Is there a decrease in Guillain-Barré syndrome incidence after bovine ganglioside withdrawal in Italy? A population-based study in the Local Health District of Ferrara, Italy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Distinct pattern of age-specific incidence of Guillain-Barré syndrome in Harbin, China

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Gastroenteritis-associated Guillain-Barré syndrome on the Caribbean island Curaçao

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Campylobacter serology in patients with Chinese paralytic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

A prospective study of acute idiopathic neuropathy. II. Antecedent events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Guillain-Barré syndrome: an Italian multicentre case-control study. Guillain-Barré Syndrome Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Preceding infections, immune factors, and outcome in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Guillain-Barré syndrome in the United States, 1979-1980 and 1980-1981. Lack of an association with influenza vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Guillain-Barré syndrome in the United States, 1978-1981: additional observations from the national surveillance system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Guillain-Barré syndrome following influenza vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Pathogenesis of Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Immunologic studies of rabies vaccination-induced Guillain-Barré syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Assessment of current diagnostic criteria for Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Subacute Idiopathic Demyelinating Polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Subacute inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Patients with chronic inflammatory demyelinating polyneuropathy initially diagnosed as Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Electrophysiology in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Electrophysiological studies in the Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Electrodiagnostic abnormalities in 113 consecutive patients with Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Early electrodiagnostic findings in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Electrodiagnostic features of the Guillain-Barré syndrome: the relative sensitivity of different techniques

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Conduction block and denervation in Guillain-Barré polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Patterns and severity of conduction abnormalities in Guillain-Barre syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Axonal involvement at the common entrapment sites in Guillain-Barré syndrome with IgG anti-GM1 antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Motor nerve biopsy in severe Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Fulminant Guillain-Barré syndrome with universal inexcitability of peripheral nerves: a clinicopathological study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Pathology of the Guillain-Barr� syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Electron microscopic studies on ordinary and hyperacute experimental allergic encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Matrix metalloproteinase-9 is increased and correlates with severity in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Immune attack on the schwann cell surface in acute inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Acute motor axonal neuropathy: An antibody-mediated attack on axolemma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Patterns of recovery in the Guillain-Barre syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

The refractory period of transmission is impaired in axonal Guillain-Barré syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Differences in patterns of progression in demyelinating and axonal Guillain-Barré syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Neuropathological findings in Miller Fisher syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Peripheral nerve conduction in Miller Fisher syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Neuropathy in the Miller Fisher syndrome: clinical and electrophysiologic findings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Brainstem encephalitis and the syndrome of Miller Fisher: a clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Identification of the neuritogen for experimental allergic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

P0 myelin protein produces experimental allergic neuritis in Lewis rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Induction of experimental autoimmune neuritis with peripheral myelin protein-22.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

CDR3 spectratyping analysis of the T cell receptor repertoire in Guillain-Barré and Fisher syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Guillain-Barre syndrome in organ and bone marrow transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

T cell responses to myelin proteins in Guillain-Barré syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

T lymphocyte recognition sites on peripheral nerve myelin P0 protein

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Antibody responses to P0 and P2 myelin proteins in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

T helper type 2 like cytokine responses to peptides from P0 and P2 myelin proteins during the recovery phase of Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Investigation of serum response to PMP22, connexin 32 and P0 in inflammatory neuropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Anti-PMP22 antibodies in patients with inflammatory neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Antibodies to gangliosides and galactocerebroside in patients with Guillain-Barré syndrome with preceding Campylobacter jejuni and other identified infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Acute motor axonal neuropathy after Mycoplasma infection: Evidence of molecular mimicry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Experimental sensory neuropathy induced by sensitization with ganglioside GD1b.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Acute motor axonal neuropathy rabbit model: immune attack on nerve root axons.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

An anti-ganglioside antibody-secreting hybridoma induces neuropathy in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Failure of anti-GM1 IgG or IgM to induce conduction block following intraneural transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

The physiological effect of anti-GM1 antibodies on saltatory conduction and transmembrane currents in single motor axons.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Antibodies against GM1 ganglioside affect K+ and Na+ currents in isolated rat myelinated nerve fibers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Serum factor in Miller-Fisher variant of Guillain-Barré syndrome and neurotransmitter release

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor end plates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Neurophysiological and immunohistochemical studies on Guillain-Barre syndrome with IgG anti-GalNAc-GD1a antibodies-effects on neuromuscular transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Anti–GM1 IgG antibodies induce leukocyte effector functions via Fcγ receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Accumulation of immunoglobulin across the 'blood-nerve barrier' in spinal roots in adoptive transfer experimental autoimmune neuritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Peripheral neuropathies and anti-glycolipid antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Pathogenicity of anti-ganglioside antibodies in the Guillain-Barré syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Patterns and serial changes in electrodiagnostic abnormalities of axonal Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

GalNAc-GD1a in human peripheral nerve: target sites of anti-ganglioside antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Localization of major gangliosides in the PNS: implications for immune neuropathies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Binding of immunoglobulin G antibodies in Guillain-Barré syndrome sera to a mixture of GM1 and a phospholipid: possible clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

The distribution of CD1 molecules in inflammatory neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Isolation and characterisation of T lymphocytes from sural nerve biopsies in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Blood gammadelta T cells, Campylobacter jejuni, and GM1 titers in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

The Guillain-Barré syndrome: a true case of molecular mimicry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Campylobacter jejuni infection and Guillain-Barré syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Does Campylobacter jejuni infection elicit "demyelinating" Guillain-Barre syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Campylobacter jejuni from patients with Guillain-Barré syndrome preferentially expresses a GD(1a)-like epitope.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

The crucial role of Campylobacter jejuni genes in anti-ganglioside antibody induction in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Monoclonal antibodies raised against Guillain-Barré syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Haemophilus influenzae has a GM1 ganglioside-like structure and elicits Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Miller Fisher syndrome and Haemophilus influenzae infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Antiganglioside antibodies in Guillain-Barré syndrome after a recent cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

HLA-DR antigens in Mexican patients with Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

HLA-class II alleles in Guillain-Barré syndrome and Miller Fisher syndrome and their association with preceding Campylobacter jejuni infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

HLA and T-cell receptor gene polymorphisms in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Differential Distribution of HLA-DQ /DR Epitopes in the Two Forms of Guillain-Barre Syndrome, Acute Motor Axonal Neuropathy and Acute Inflammatory Demyelinating Polyneuropathy (AIDP): Identification of DQ Epitopes Associated with Susceptibility to an

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Differential distribution of HLA alleles in two forms of Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

HLA class II alleles are not a general susceptibility factor in Guillain-Barré syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Severity of Guillain-Barré syndrome is associated with Fc gamma Receptor III polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain-Barré patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Genetic contribution of the tumor necrosis factor region in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Residual neuropathy in long-term population-based follow-up of Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Guillain-Barré syndrome in children: clinical course, electrodiagnosis, and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Childhood Guillain-Barré syndrome: clinical and electrophysiologic features predictive of outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Mild Guillain-Barré syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Recovery patterns and long term prognosis for axonal Guillain-Barré syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Supportive care for patients with Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Rehabilitation of Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Long-term impact on work and private life after Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Residual health status after Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Residual physical outcome and daily living 3 to 6 years after Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Electrophysiological signs of permanent axonal loss in a follow-up study of patients with Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Physical training and fatigue, fitness, and quality of life in Guillain-Barré syndrome and CIDP.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Appropriate number of plasma exchanges in Guillain-Barré syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Cost analysis of plasma-exchange therapy for the treatment of Guillain-Barré syndrome. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Intravenous immunoglobulin in autoimmune neuromuscular diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Practice parameter: Immunotherapy for Guillain-Barre syndrome: Report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Intravenously Administered Immunoglobulin in the Treatment of Childhood Guillain-Barre Syndrome: A Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Loss of electrical excitability in an animal model of acute quadriplegic myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Sodium channel inactivation in an animal model of acute quadriplegic myopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Synthetic disialylgalactose immunoadsorbents deplete anti-GQ1b antibodies from autoimmune neuropathy sera

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

Randomized controlled trial of brain-derived neurotrophic factor in Guillain-Barré syndrome: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967665-9

7 January 2021

10.1016/S0140-6736(05)67665-9

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

423461

423461

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference